ESTRO 2025 - Abstract Book

S1943

Clinical - Urology

ESTRO 2025

1441

Digital Poster Real World Data analysis in nmCRPC treated with Darolutamide

María Elena Centelles 1 , Pedro De-Pablos 2 , Ana María Carballo 3 , Miguel Rodrigo 4 , Mario Dominguez 5 , Miguel Angel Berenguer 6 , Raquel Garcia 7 , Sara Alvarez 8 , Teresa Alonso 9 , Odile Ajuria 10 , Asunción Hervás 9 , Carmen Vallejo 9 , Marta Camacho 9 , Sandra González-Montiel 11 , Juan Carlos Yúfera 11 , Sonsoles Sancho 9 , Fernando López-Campos 9 1 Radiation Oncology, H.U.G. Elche, Elche, Spain. 2 Radiation Oncology, IVO, Valencia, Spain. 3 Radiation Oncology, H.U. Santiago de Compostela, Santiago de Compostela, Spain. 4 Radiation Oncology, H.U.G. Castellón, Castellón, Spain. 5 Radiation Oncology, H.U. Marqués de Valdecillas, Santander, Spain. 6 Radiation Oncology, H.U. La Fé, Valencia, Spain. 7 Radiation Oncology, H.U.Clínico de Valencia, Valencia, Spain. 8 Urology, H.U.Ramón y Cajal, Madrid, Spain. 9 Radiation Oncology, H.U.Ramón y Cajal, Madrid, Spain. 10 Nuclear Medicine, H.U.Ramón y Cajal, Madrid, Spain. 11 Radiation Oncology, H.U.G.E, Elche, Spain Purpose/Objective: The ARAMIS study, a phase III clinical trial, assessed Darolutamide's efficacy and safety in non-metastatic castration resistant prostate cancer(nmCRPC). The aim of our analysis is to assess in real-world data the clinical response and metastasis-free survival(MFS) of nmCPRC patients treated with Darolutamide as well as its safety and toxicity, emphasizing the use of Charlson comorbidity index(CCI). Material/Methods: Retrospectively, we evaluated consecutive patients diagnosed of nmCRPC treated with Darolutamide across seven Spanish cancer-centers between 2022 and 2024. Patients baseline characteristics are described in table 1 and timeline analysis for oncologic outcomes are describe in table 2. To analyze our results, with median CCI of 2(0 11), we registered polimedication observing >6 drugs in 39(39%) patients. Univariate analysis was conducted to summarize factors influencing toxicity, response, and safety outcomes, using medians, interquartile ranges(IQR) and percentages.